CB₁ Reverse Agonists: A Cheminformatic and Patent Landscape Study

Year : 2025 | Volume : 03 | Issue : 02 | Page : 33 36
    By

    Deepak Sharma,

  1. Student, CSE Department, VIT Bhopal University, Kothrikalan, Sehore, Madhya Pradesh, India

Abstract

The endocannabinoid system plays a crucial role in numerous physiological functions, making cannabinoid receptor 1 (CB1) an attractive target for therapeutic development. This review provides a systematic analysis of patent filings from 2019 to 2023 that focus on small-molecule CB1 reverse agonists. It begins with an overview of the endocannabinoid system, highlighting CB1’s involvement in energy balance, pain regulation, and neuroinflammatory processes The main section of the review examines fifteen patents covering diverse structural classes—such as pyrazoles, triazoles, and piperidines—designed to achieve high CB1 affinity and efficacy. Evaluation of these patents uncovers innovative scaffolds aimed at enhancing receptor selectivity, limiting central nervous system penetration, and improving pharmacokinetic characteristics. Many of the patented compounds target metabolic disorders, including obesity and type 2 diabetes, by modulating CB1 signaling in peripheral tissues. Other therapeutic areas addressed include chronic pain, neurodegenerative conditions, and substance use disorders. Each patent is analyzed for its inventive aspects, synthetic feasibility, and reported in vitro and in vivo results Insights from industry expert interviews underscore ongoing challenges, such as maintaining a favorable safety profile, preventing neuropsychiatric side effects, and addressing formulation difficulties. The review concludes by highlighting emerging trends and suggesting future directions for CB1 reverse agonist development. Recommendations include using structure–activity relationship studies to fine-tune central versus peripheral activity, applying advanced drug-delivery approaches, and incorporating biomarker-driven clinical strategies. By integrating recent patent data and expert perspectives, this review seeks to guide medicinal chemists and pharmacologists in advancing CB1-focused drug discovery.

Keywords: Cannabinoid signaling pathway, CB1 receptor, pharmacological reverse agonists, patent filings, metabolic disease management, CB1 antagonism

[This article belongs to International Journal of Cheminformatics ]

How to cite this article:
Deepak Sharma. CB₁ Reverse Agonists: A Cheminformatic and Patent Landscape Study. International Journal of Cheminformatics. 2025; 03(02):33-36.
How to cite this URL:
Deepak Sharma. CB₁ Reverse Agonists: A Cheminformatic and Patent Landscape Study. International Journal of Cheminformatics. 2025; 03(02):33-36. Available from: https://journals.stmjournals.com/ijci/article=2025/view=230327


References

  1. Kangas BD, Delatte MS, Vemuri VK, Thakur GA, Nikas SP, Subramanian KV, Shukla VG, Makriyannis A, Bergman J. Cannabinoid discrimination and antagonism by CB1 neutral and inverse agonist antagonists. The Journal of pharmacology and experimental therapeutics. 2013 Mar 1;344(3):561-7.
  2. Wills KL, DeVuono MV, Limebeer CL, Vemuri K, Makriyannis A, Parker LA. CB₁ receptor antagonism in the bed nucleus of the stria terminalis interferes with affective opioid withdrawal in rats. Behavioral Neuroscience. 2017 Aug;131(4):304.
  3. Weresa J, Pędzińska-Betiuk A, Kossakowski R, Malinowska B. Cannabinoid CB1 and CB2 receptors antagonists AM251 and AM630 differentially modulate the chronotropic and inotropic effects of isoprenaline in isolated rat atria. Pharmacological Reports. 2019 Feb 1;71(1):82-9.
  4. Khajehali E. Validation and quantification of ligand-biased signalling and allosteric modulation at CB₁ cannabinoid receptors (Doctoral dissertation, Monash University).
  5. Muccioli GG. Blocking the Cannabinoid Receptors: Drug Candidates and Therapeutic. Cannabinoids in Nature and Medicine. 2009 Sep 28:223.
  6. Pertwee RG. The Pharmacology and Therapeutic. Cannabinoids. 2004 Jun 29:32.
  7. Kregiel J, Malek N, Popik P, Starowicz K, Rygula R. Retraction Notice to “Anandamide mediates cognitive judgement bias in rats”[Neuropharmacology 101 (2016) 146–153].
  8. Schuehly W, Paredes JM, Kleyer J, Huefner A, Anavi-Goffer S, Raduner S, Altmann KH, Gertsch J. Mechanisms of osteoclastogenesis inhibition by a novel class of biphenyl-type cannabinoid CB2 receptor inverse agonists. Chemistry & biology. 2011 Aug 26;18(8):1053-64.
  9. Campos GS, Sanchez-Lopez A, León CA, Zafra ÁM, Cano IC, Rodríguez ME, Ruiz JM. Role of neuronal orientation on cerebellar transcranial direct-current stimulation (cb-tDCS) effects in awake mice. IBRO Neuroscience Reports. 2023 Oct 1;15:S319-20.
  10. Rock EM, Limebeer CL, Mechoulam R, Piomelli D, Parker LA. ” The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat”: Erratum.
Regular Issue Subscription Review Article
Volume 03
Issue 02
Received 16/10/2025
Accepted 24/10/2025
Published 30/10/2025
Publication Time 14 Days
41

Login


My IP

PlumX Metrics